ucb0599
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 6, 2019 (NCT04875962)
Timeline
Indications
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06533475 | Phase 1 | Sep 6, 2024 | UCB |
| NCT05845645 | Phase 1 | May 31, 2023 | UCB |
| NCT05543252 | Phase 2 | Aug 29, 2022 | UCB |
| NCT04658186 | Phase 2 | Dec 31, 2020 | UCB |
| NCT04875962 | Phase 1 | May 6, 2019 | UCB |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UCB | For profit | 5 | 5 | 2 | 2019 |
1 organizations
Page 1 / 1